Abstract
Objectives:
Chronic heart failure (CHF) is a chronic and progressive disease with high incidence. The aim of this study was to evaluate the effectiveness and safety of Xinmailong injection (XI) on CHF patients with B-type natriuretic peptide (BNP) ≥200 ng/mL and left ventricular ejection fraction (LVEF) of ≤45%.
Trial design:
This is a randomized double-blind placebo-controlled trial.
Settings:
Hospitals.
Subjects:
One hundred patients with CHF were randomly divided into XI (n = 50) and control groups (n = 50).
Intervention:
The XI group was treated with standard treatment plus XI (100 mg/2 mL, intravenous drip infusion). The control group was treated with standard treatment plus equal amounts of XI placebo. The course of treatment was 5 days.
Outcome measures:
New York Heart Association (NYHA) functional class, LVEF, BNP, and 6-min walking distance were assessed for therapeutic effect.
Results:
NYHA functional classes and LVEF were better in the XI group than in the control (p < 0.01). BNP was significantly different after the treatments in both groups (p < 0.01), and compared with the control, BNP was reduced after XI treatment (p < 0.01). No deaths occurred in the course of this study. The number of adverse events between the two groups was not statistically different (p > 0.05).
Conclusions:
XI can alleviate the symptoms, improve heart function, and exercise tolerance in patients with CHF and is safe to use.
Get full access to this article
View all access options for this article.